Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 1.6% – What’s Next?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) fell 1.6% on Wednesday . The stock traded as low as $3.60 and last traded at $3.63. 11,369 shares traded hands during trading, a decline of 47% from the average session volume of 21,285 shares. The stock had previously closed at $3.69.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Cyclerion Therapeutics Stock Performance

The company has a market capitalization of $14.95 million, a P/E ratio of -2.55 and a beta of 1.74. The firm’s fifty day moving average is $3.31 and its 200 day moving average is $2.51.

Cyclerion Therapeutics (NASDAQ:CYCN) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($17.20) by $16.44. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative return on equity of 62.10%. On average, analysts forecast that Cyclerion Therapeutics, Inc. will post -1.2 EPS for the current year.

Institutional Investors Weigh In On Cyclerion Therapeutics

A hedge fund recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP acquired a new stake in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned 0.40% of Cyclerion Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 75.62% of the company’s stock.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.